Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246963 | 0.86 | PTPN1 (0.49) | PTPN1KMT2AMDM2MCHR1 | |
| SCHEMBL2247071 | 0.86 | PTPN1 (0.54) | PTPN1KMT2AMDM2MDM4TP53 | |
| SCHEMBL2249376 | 0.85 | PTPN1 (0.52) | PTPN1KMT2AMDM2MDM4TP53 | |
| SCHEMBL2245613 | 0.85 | PTPN1 (0.48) | PTPN1KMT2AMDM2MDM4TP53 | |
| SCHEMBL3576902 | 0.85 | KMT2A (0.54) | PTPN1KMT2AMDM4TP53TLR2 | |
| SCHEMBL2244684 | 0.84 | PTPN1 (0.50) | PTPN1KMT2AMDM2MCHR1TLR2 | |
| SCHEMBL2252403 | 0.83 | PTPN1 (0.47) | PTPN1KMT2AMDM2 | |
| SCHEMBL12156602 | 0.82 | PTPN1 (0.54) | PTPN1KMT2ATLR2 | |
| SCHEMBL2247631 | 0.82 | PTPN1 (0.52) | PTPN1KMT2AMDM2MDM4TP53 | |
| SCHEMBL2248960 | 0.82 | PTPN1 (0.52) | PTPN1KMT2AMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | PTPN1 4403/4885KMT2A 2364/4885MDM2 2939/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | PTPN1 4403/4885KMT2A 2364/4885MDM2 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.